Targeting CD38 with Daratumumab in a Newly Diagnosed Case of POEMS Syndrome with a 17p Deletion in a Solitary Plasmacytoma of the Bone: A Case Study and Literature Review.

Abstract

Daratumumab-based induction therapy and autologous stem cell transplantation (ASCT) as a treatment of newly diagnosed POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder, Skin changes) have been rarely studied. Here, we present a young patient with newly diagnosed POEMS syndrome harboring a 17p deletion in a solitary plasmacytoma of the bone, who was treated with systemic therapy comprising daratumumab combined with lenalidomide dexamethasone, local radiotherapy, and ASCT. To date, he has achieved 18 months of continuous complete remission with respect to hematological parameters and vascular endothelial growth factor levels (HRCR and VCR), with an overall neuropathy limitations scale score of 3 for both upper limbs and 2 for both lower limbs, thereby enabling independent walking. These data suggest that using daratumumab as a front-line treatment might lead to deeper remission and better quality of life for young patients with POEMS.